Article: Immunologic therapy helps Graves' disease
Ophthalmology Times;  March 1, 2001 ;     700+ words ...DALLAS-Immunologic interventions for acute Graves' disease that will allow early arrest of the ophthalmic inflammatory manifestations and interrupt the development of scarring and anatomic changes may be on the horizon, said Jonathan J. Dutton, MD, PhD, former professor of ophthalmology, Duke

Article: Studies from Baylor College of Medicine, College of Medicine ...
Biotech Week;  September 10, 2008 ;     700+ words ... ... importance to appropriately screen all patients for latent TB infection prior to initiating any immunologic therapy. Delaying immunologic therapy until latent TB infection prophylaxis is completed is preferable," wrote S.D. Doherty and ...

Article: Photodynamic therapy finally arrives
Dermatology Times;  October 1, 2001 ;     700+ words ... ... and Paget's disease. Non-cancer conditions In non-ontological conditions, "PDT should be considered for immunologic therapy," Dr. Lui said. A primary reason is that activated T-cells are preferentially photosensitized by ALA. There ...

Article: ZLB Bioplasma Forms Physician Advisory Board.
Business Wire;  February 13, 2002 ;     522 words ... ... immune globulin or gamma globulin scientific physician advisory board to assess trends in medical immunology or immunologic therapy and provide strategic counsel. Richard L. Wasserman, M.D., Ph.D., Clinical Associate Professor of Pediatrics ...

Article: Immunotherapy Gets Dramatic Results For Rare Disorder.(stiff ...
Immunotherapy Weekly;  January 16, 2002 ;     700+ words ...2002 JAN 16 - (NewsRx.com & NewsRx.net) -- An immunologic therapy, intravenous immunoglobulin (i.v. Ig), administered to patients suffering from stiff person syndrome (SPS), provides ...

Article: CFS Treatments a Mixed Fix. (Clinical Capsules).(chronic fatigue ...
Clinical Psychiatry News;  November 1, 2001 ;     545 words ... ... greatest overall benefits, compared with control groups. Two of five randomized, controlled trials involving immunologic therapy showed an overall beneficial effect, as did one randomized, controlled trial using drug therapy (oral reduced ...

Article: Dendreon Announces Presentation of Promising Provenge Phase III ...
Business Wire;  September 20, 2002 ;     700+ words ... ... the treatment of advanced prostate cancer patients, so that the potential development of relatively non-toxic immunologic therapy is exciting." The trial involved 127 men with metastatic, hormone resistant prostate cancer, 82 of whom received ...